You are here: Industry Insights > BMS

News List

BMS links with Apexigen to test cancer immunotherapy combo pharmatimes
April 14, 2017
Bristol-Myers Squibb and Apexigen are to test a combination of Opdivo and the latter’s investigational compound APX005M in patients with advanced solid tumours.
BMS and Apexigen collaborate to evaluate Opdivo in combination with APX005M in advanced solid tumour cphi-online
April 14, 2017
Study to evaluate potential of APX005M plus Opdivo to activate antigen-presenting cells in the tumour micro-environment to demonstrate enhanced anti-tumour activity.
BMS and Apexigen to Evaluate Opdivo in Combination with APX005M in Advanced Solid Tumors americanpharmaceuticalreview
April 12, 2017
Bristol-Myers Squibb Company and Apexigen, Inc. announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Apexigen’s APX005M in patients with advanced solid tumors.
The first overall survival data from the Phase 3 CheckMate -067 clinical trial worldpharmanews
April 05, 2017
Bristol-Myers Squibb Company (NYSE:BMY) today announced the first overall survival (OS) data from the Phase 3 CheckMate -067 clinical trial.
BMS receives positive CHMP opinion recommending Opdivo for head and neck cancer cphi-online
March 29, 2017
Opdivo already approved by the EC for six indications in four distinct tumour types.
BMS Receives Positive CHMP Opinion Recommending Opdivo for the Treatment of Squamous Cell Cancer of americanpharmaceuticalreview
March 27, 2017
Bristol-Myers Squibb Company has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Opdivo...
BMS, CytomX Expand Probody Pact contractpharma
March 21, 2017
BMS gains worldwide rights to develop and commercialize as many as six additional oncology targets
Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ The americanpharmaceuticalreview
March 21, 2017
Bristol-Myers Squibb Company and CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer...
BMS appoints Dr Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer cphi-online
March 10, 2017
He succeeds Dr Francis Cuss, 62, who will retire from the company.
BMS Names EVP, CSO contractpharma
March 10, 2017
Lynch brings 30 years of medical, management and leadership experience

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page